In alcohol use disorder and comorbid obesity, weekly semaglutide reduced heavy drinking days at 26 wk

The authors investigate whether weekly administration of semaglutide can reduce heavy drinking days in individuals with alcohol use disorder and comorbid obesity. Their findings indicate that semaglutide treatment led to a significant reduction in heavy drinking days over a 26-week period. This suggests a potential therapeutic role for semaglutide in managing alcohol use disorder in this patient population.